The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
Researchers at Uppsala University have developed a new method for very rapidly determining whether infection-causing bacteria are resistant or susceptible to antibiotics.
In2Bones said today that its US subsidiary received FDA clearance for its 5MS Fracture repair and CoLag locking compression screw systems.
RealView Imaging has integrated the Intel RealSense SR300-Series camera into its holographic augmented reality (AR) medical system, Holoscope-i.
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
Fortimedix Surgical said today it launched a shorter set of instruments for its SymphonX single-port surgical platform in the US.
FDA extends review on Dynavax's hepatitis B vaccine candidate Heplisav-B, but both management and analysts said they remain confident in approval.
US researchers from Harvard University’s SEAS and the Wyss Institute for Biologically Inspired Engineering have developed a small, hybrid rigid-soft robotic arm for endoscopes.
The merger and acquisition information of CombiMatrix, Skyline Medical and Victory Square Technologies.
Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.